Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals

References

• Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C virus epidemiology and the impact of interferon-free hepatitis C virus therapy. Cold Spring Harb Perspect Med. 2020;10(3):a036913.
   PubMed Web of Science ®Google Scholar
• Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36(2):91–133.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Elbaz T, Elsharkawy A, et al. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev Anti Infect Ther. 2018;16(4):345–350.
   PubMed Web of Science ®Google Scholar
• Omran D, Alboraie M, Zayed RA, et al. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol. 2018;24(38):4330–4340.
   PubMed Web of Science ®Google Scholar
• El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017;24(4):262–267.
   PubMed Web of Science ®Google Scholar
• Gomaa A, Allam N, Elsharkawy A, et al. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med. 2017;9:17–25.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Alboraie M, Omran D, et al. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018;12(12):1265–1272.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Elbaz T, Hafez E, et al. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. Expert Opin Drug Saf. 2016;15(12):1643–1652.
   PubMed Web of Science ®Google Scholar
• Esmat G, El Kassas M, Hassany M, et al. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int. 2014;34(1):24–28.
   PubMed Web of Science ®Google Scholar
• Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421–431.
   Web of Science ®Google Scholar
• Eletreby R, Elakel W, Said M, et al. Real life Egyptian experience of efficacy and safety of simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37(4):534–541.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Alboraie M, Omar H, et al. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: real world results. J Med Virol. 2019. DOI:10.1002/jmv.25478
   PubMed Web of Science ®Google Scholar
• Fusco F, D’Anzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother. 2013;14(18):2533–2544.
   PubMed Web of Science ®Google Scholar
• Gentile I, Fusco F, Buonomo AR, et al. Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. Sex Health. 2018;15(5):408–412.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction (3). J Sex Med. 2010;7(1 Pt 2):445–475.
   PubMed Web of Science ®Google Scholar
• Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.
   PubMed Web of Science ®Google Scholar
• Salonia A, Castagna G, Saccà A, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. J Sex Med. 2012;9(10):2708–2715.
   PubMed Web of Science ®Google Scholar
• Chung SD, Keller JJ, Liang YC, et al. Association between viral hepatitis and erectile dysfunction: a population-based case-control analysis. J Sex Med. 2012;9(5):1295–1302.
   PubMed Web of Science ®Google Scholar
• Durazzo M, Premoli A, Di Bisceglie C, et al. Alterations of seminal and hormonal parameters: an extrahepatic manifestation of HCV infection? World J Gastroenterol. 2006;12(19):3073–3076.
   PubMed Web of Science ®Google Scholar
• Soykan A, Boztaş H, Idilman R, et al. Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables. Int J Impot Res. 2005;17(2):175–179.
   PubMed Web of Science ®Google Scholar
• Triantos CK, Tsintoni A, Karaivazoglou K, et al. Male hepatitis C patients’ sexual functioning and its determinants. Eur J Gastroenterol Hepatol. 2017;29(11):1241–1246.
   PubMed Web of Science ®Google Scholar
• Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139(3):161–168.
   PubMed Web of Science ®Google Scholar
• Elshimi E, Morad W, Mohamad NE. Male sexual dysfunction among Egyptian patients with chronic hepatitis C virus infection before and after direct-acting antiviral drugs. J Sex Med. 2019;16(3):402–409.
   PubMed Web of Science ®Google Scholar
• Shamloul R, Ghanem H, Abou-Zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res. 2004;16(5):452–455.
   PubMed Web of Science ®Google Scholar
• Rosen RC. Prevalence and risk factors of sexual dysfunction in men and women. Curr Psychiatry Rep. 2000;2(3):189–195.
   PubMedGoogle Scholar
• Anis TH, Gheit SA, Saied HS, Al Kherbash SA. Arabic translation of Female Sexual Function Index and validation in an Egyptian population. J Sex Med. 2011;8(12):3370–3378.
   PubMed Web of Science ®Google Scholar
• Karaivazoglou K, Tsermpini EE, Assimakopoulos K, et al. Sexual functioning in patients with chronic hepatitis C: a systematic review. Eur J Gastroenterol Hepatol. 2017;29(11):1197–1205.
   PubMed Web of Science ®Google Scholar
• Vergniol J, Duc S, Hou G, et al. Sexual quality of life is impaired in patients with chronic hepatitis C. Int J Impot Res. 2016;28(2):68–73.
   PubMed Web of Science ®Google Scholar
• Ferri C, Bertozzi MA, Zignego AL. Erectile dysfunction and hepatitis C virus infection. JAMA. 2002;288(6):698–699.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Vicari E, Calogero A, et al. Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin. J Interferon Cytokine Res. 2008;28(10):603–609.
   PubMed Web of Science ®Google Scholar
• Baranyi A, Meinitzer A, Stepan A, et al. A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection. Psychother Psychosom. 2013;82(5):332–340.
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology. 1999;29(1):264–270.
   PubMed Web of Science ®Google Scholar
• Elshimi E, Sakr N, Morad W, et al. Direct-acting antiviral drugs improve the female sexual burden associated with chronic HCV infection. Expert Rev anti Infect Ther. 2019;17(11):919–926.
   PubMed Web of Science ®Google Scholar